

Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents



Greta A. Bushnell, PhD,¹ Stephen Crystal, PhD,² Mark Olfson, MD^{1,3}

Introduction: Benzodiazepines are commonly prescribed in the U.S. but entail safety concerns, including dependency. In pediatrics, many indications lack trial data. Authors aimed to describe youth initiating prescription benzodiazepine treatment, identify potential indications and prescribing concerns, estimate the duration of treatment by potential indication, and identify factors that predict long-term use.

Methods: The study cohort included children (aged 3–12 years) and adolescents (aged 13–17 years) initiating prescription benzodiazepine treatment (≥ 3 days' supply) from January 2010 to September 2015 in a U.S. commercial claims database. Potential indications included selected ICD-9-CM diagnoses (≤ 30 days prior). Long-term (≥ 6 months) benzodiazepine treatment was estimated with Kaplan–Meier estimation and modified Poisson regression identified independent predictors of long-term benzodiazepine treatment (analysis completed in 2018).

Results: Of 24,504 children and 61,046 adolescents initiating benzodiazepines, 62% of the children and 68% of the adolescents had a potential indication. Anxiety disorders were the most common indication, with mental health indications more common among adolescents (45%) than children (23%) and epilepsy and movement disorders higher in children. Recent opioid prescriptions were common before benzodiazepine initiation (children, 22%; adolescents, 21%). Six percent of the initiators became long-term benzodiazepine users. Potential indication, provider contact, psychotropic medication, and chronic conditions independently predicted long-term benzodiazepine treatment in adolescents and children.

Conclusions: U.S. children and adolescents are prescribed benzodiazepines for various mental health and other medical conditions, many lacking evidence of pediatric efficacy. Long-term benzodiazepine treatment, concurrent opioid prescriptions, psychotropic use, and prior substance use disorder diagnoses suggest safety risks among some youth prescribed benzodiazepines.

Am J Prev Med 2019;57(6):775–785. © 2019 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

INTRODUCTION

Benzodiazepines are commonly prescribed in the U.S.,^{1,2} with 62.6 million ambulatory care visits in which benzodiazepines were prescribed in 2015.³ The use of benzodiazepines increases with age^{1,4}; the prescribing rates in young adults (aged 18–24 years) are approximately four to seven times those in children.⁵ Still, in the past 30 days, 0.6% of U.S. children aged 0–19 years report prescription of benzodiazepines or other anxiolytics, sedatives, or hypnotics.⁶ Considering cumulative exposure to prescribed medication and non-prescription use, a tenth of U.S. high school seniors report prior benzodiazepine exposure.⁷

There are safety concerns with benzodiazepine treatment, including mild memory impairment, decreased alertness, slowed reaction time,⁸ and benzodiazepine

From the ¹Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York; ²Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey; and ³Department of Psychiatry, Columbia University Irving Medical Center, New York, New York

Address correspondence to: Greta A. Bushnell, PhD, Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168th Street, Room 720-C, New York NY 10032. E-mail: gb2612@cumc.columbia.edu.

0749-3797/\$36.00

<https://doi.org/10.1016/j.amepre.2019.07.006>

dependence, prompting guidelines to confine their use to the short term.⁹ Nevertheless, longer-term benzodiazepine use is common, including in pediatrics.^{10–15} Benzodiazepines, central nervous system depressants, are involved in drug overdose deaths,¹⁶ including a third of opioid-related fatalities,¹⁷ and have been associated with motor vehicle accidents and fractures in adults.^{18–20} Among youth, nonmedical benzodiazepine use can follow prescription treatment, emphasizing the need for cautious and monitored use in young people.⁷

Despite safety concerns, benzodiazepines can be useful medications when prescribed appropriately.²¹ Given sedative, anxiolytic, anticonvulsant, and muscle relaxation effects, adults are prescribed benzodiazepines for a range of clinical indications, including anxiety disorders, sleep problems, and mood disorders.^{2–4,11,22} Physicians also prescribe benzodiazepines as muscle relaxants for pain.^{3,23} In older adults, benzodiazepines are commonly (42%) prescribed without a recommended indication.²⁴ Although the U.S. Food and Drug Administration approved benzodiazepines for the treatment of selected conditions in adults, benzodiazepines remain unapproved for pediatric use outside of epilepsy and seizures. Benzodiazepines demonstrated efficacy for treating adult anxiety disorders but failed to show efficacy over a placebo in the few trials of pediatric anxiety disorders.^{25–28} Similarly, the evidence and recommendations for benzodiazepine treatment in sleep disorders varies for adults and pediatrics.^{29,30}

Although there are no firmly established indications for benzodiazepines for the treatment of pediatric mental health disorders,³¹ benzodiazepines are prescribed to children to treat mental health conditions, including anxiety and sleep disorders.^{15,32,33} A Swedish study revealed that half of the adolescents prescribed benzodiazepines had a mental health disorder diagnosis in the months surrounding benzodiazepine initiation; anxiety and depression were the most frequent.³³ In the Swedish sample of children with new treatment periods, 29% lasted >6 months.³³ Recent publications provided important insights into prescription benzodiazepine use in U.S. adults.^{3,34,35} However, in U.S. children, the treated conditions and duration of treatment across indications have not been described.

To define whether and where improvements in pediatric benzodiazepine prescribing are needed in clinical practice, it is important to understand why benzodiazepines are prescribed to this young population and to identify patient groups likely to receive long-term benzodiazepine treatment. In addition, examining benzodiazepine prescribing practices separately in children and adolescents can be informative given the results in other young populations³³ and the developmental changes

occurring from childhood to adolescence.³⁶ Therefore, the authors aimed to describe children and adolescents who initiated prescription benzodiazepine treatment, potential indications and prescribing concerns, duration of treatment by potential indication, and predictors of long-term use.

METHODS

Study Sample

This study utilized the MarketScan administrative claims database using data from January 1, 2009 through December 31, 2015. The database covers individuals with employer-sponsored health insurance and their dependents. In 2016, >40 million lives were covered.³⁷ Patient-level details on insurance enrollment and insurance claims for outpatient and inpatient services and outpatient dispensed prescriptions are available. Service visits contain information on date, provider type, diagnostic codes, and procedure codes. Prescription drug data include dispensing dates, drug names, and days supplied.

The authors identified children (aged 3–12 years) and adolescents (aged 13–17 years) initiating benzodiazepines between January 1, 2010 and September 30, 2015 (before the switch from ICD-9-CM to ICD-10-CM codes). Benzodiazepine treatment was defined as dispensed prescriptions for alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, and triazolam. Benzodiazepines taken orally were included, excluding other administrative routes. The authors identified the first prescription per individual during the study period and then restricted their examination to new use. To identify new use, this study required a year of continuous prescription insurance enrollment before the individual's first benzodiazepine prescription. The cohort was restricted to youth initiating benzodiazepines with ≥ 3 days' supply, thereby excluding 45% of the initiators. Youth with 1–2 days' supply likely include benzodiazepines prescribed in relation to a medical procedure. The study was submitted to the Rutgers University IRB and determined to be exempt.

Measures

To identify potential indications for benzodiazepine treatment, the authors identified ICD-9-CM diagnostic codes ≤ 30 days before or upon benzodiazepine initiation ([Appendix Table 1](#), available online). Given limited pediatric approvals and recommendations for benzodiazepines, indications clinically suggested for adults were included. Primary potential indications included anxiety disorders, epilepsy or convulsions, and insomnia or sleep problems, for which there are limited pediatric recommendations.^{8,28,30,38,39} Other mental health diagnoses considered potential indications were depression,^{40,41} bipolar disorder, schizophrenia, and other psychotic disorders.^{8,42,43} Diagnoses for conduct and disruptive behavior disorders (not including attention-deficit hyperactivity disorder) were included.^{24,44,45} Diagnostic codes for irritability and impulsiveness were included in a residual "other" group.

Given the muscle relaxant effects of benzodiazepines, potential indications under "movement disorders, muscle spasm" included cerebral palsy, tics, muscular dystrophies and other myopathies,

motor neuron diseases, abnormal movement disorders, muscle spasms, and abnormal involuntary movement diagnoses.^{8,46–51} Also under “other” were alcohol withdrawal,^{8,52} burning mouth syndrome,⁵³ and trigeminal neuralgia.⁵⁴ Based on preliminary results and the broader use of benzodiazepines as muscle relaxants for muscle discomfort from acute injury or chronic musculoskeletal pain and musculoskeletal conditions,^{55–57} the authors added potential indications for injury and “diseases of musculoskeletal system and connective tissue.”

For the initial benzodiazepine prescription, agent, days supplied, and duration of action (long-acting: chlorthalidoxepoxide, clonazepam, lorazepam, diazepam, flurazepam, and clonazepam) were noted.

Factors potentially placing youth at heightened risk of benzodiazepine adverse effects were identified based on diagnoses in the ≤ 365 days before or on benzodiazepine initiation (Appendix Table 1, available online). Cautions included diagnoses for drug or alcohol-related disorders,²⁸ suicidal ideation or suicide attempt or self-harm, and poisoning.¹⁶ Diagnoses of sleep apnea, hypersomnia, respiratory failure, and hypoxemia were included given the respiratory depressant effects of benzodiazepines.^{9,30} Given strict warnings against concurrent benzodiazepine and opioid use,⁵⁸ opioid prescriptions dispensed within the 30 days before or on benzodiazepine initiation were identified.

Additional patient details included recent (≤ 30 days before or on benzodiazepine initiation) mental health diagnosis (ICD-9-CM: 290–319), psychiatric (primary or secondary diagnosis: 290–319) and nonpsychiatric inpatient admission, and psychotropic prescriptions (selective serotonin reuptake inhibitor, other antidepressant, stimulant, atomoxetine, hydroxyzine, clonidine, guanfacine, antipsychotic). Recent contact with provider types included categories for mental health, general, and medical specialist provider types. The pediatric complex chronic conditions classification system⁵⁹ was used to measure heightened medical complexity and morbidity (inpatient ICD-9-CM codes, the year before benzodiazepine initiation).

Benzodiazepine treatment duration was estimated with prescription dispensing dates and days’ supply information. If there was no benzodiazepine refill following the initial days’ supply plus a 30-day grace period, the patient was considered to have discontinued treatment (discontinuation date). Switching to a new benzodiazepine agent was considered treatment continuation. Treatment duration (days between initiation and discontinuation date) ≥ 6 months (180 days) was considered long-term benzodiazepine treatment. This definition was selected to be consistent with the prior literature.¹² For a sensitivity analysis, treatment duration was defined using narrower (10-day) and broader (60-day) grace periods.

Statistical Analysis

This study described children and adolescents initiating benzodiazepine treatment and examined the proportion with each potential indication, prescribing caution, and other patient characteristic. Crude prevalence ratios for child versus adolescent initiators highlighted relative differences. Potential indications were evaluated by sex and, for a sensitivity analysis, in youth without a recent inpatient hospitalization because prescriptions dispensed in the hospital were unavailable in the data set. Initial benzodiazepine details were stratified by potential indication. Using Kaplan–Meier estimation, the authors estimated the treatment duration

stratified by potential benzodiazepine indication, censoring at treatment discontinuation, insurance disenrollment, or the end of data. The treatment duration was evaluated in youth with diagnoses for each potential indication (e.g., epilepsy) and in the subset of youth with only one potential indication (e.g., epilepsy and no other potential indication). To identify whether potential indications and other patient characteristics independently predicted long-term benzodiazepine treatment, the authors used a modified Poisson regression with robust variance estimation, which allowed the estimation of multivariable RRs and 95% CIs.⁶⁰ This analysis was restricted to youth with ≥ 6 months of follow-up with long-term treatment defined under a 30-day grace period. Separate models were constructed for children and adolescents. Analyses were completed in 2018 in SAS, version 9.4.

RESULTS

The cohort included 24,504 children (median age, 9 years) and 61,046 adolescents (median age, 16 years) initiating a benzodiazepine with ≥ 3 days’ supply. Forty-six percent of child initiators and 60% of adolescent initiators were female. Diazepam, lorazepam, alprazolam, and clonazepam were the most common initial benzodiazepine agents (Table 1). The median initial prescription length was 10 days (IQR=5–30 days).

Overall, 67% of benzodiazepine initiators had at least one potential indication (Table 1). Anxiety disorders were the most prevalent potential indication, accounting for 28% of the initiators (children, 17%; adolescents, 32%). In adolescents, 45% had a potential mental health indication, nearly twice as common as child initiators (23%), with few initiators having sleep problem diagnoses. Nineteen percent of adolescents had a recent depression diagnosis, half of these also having an anxiety diagnosis. Epilepsy and movement disorders were identified as potential indications in a greater proportion of child than adolescent initiators.

Considering sex, the largest absolute differences were seen in more female adolescent initiators with an anxiety or depression diagnosis and in more male adolescent initiators with an injury diagnosis (Appendix Figure 1, available online). Among children, the largest difference was a higher proportion of female (5%) than male (2%) initiators with spine curvature diagnoses.

Benzodiazepine agent and days’ supply varied by potential indication (Appendix Table 2, available online). Initiators with potential indications of sleep problems, depression, bipolar disorder or schizophrenia, or conduct disorder received longer initial days’ supply. Initiators with an injury or musculoskeletal condition were more likely to initiate on diazepam with shorter days’ supply. A majority (86%) of the youth initiating triazolam had no potential indication, compared with 26%–36% for other common initial agents.

Table 1. Potential Indications in Children and Adolescents Initiating Prescription Benzodiazepine Treatment

Variable	Total, % (n=85,550)	Children, 3–12 years, % (n=24,504)	Adolescents, 13–17 years, % (n=61,046)	Child vs Adolescent, Crude PR (95% CI)
Patient, prescribing characteristics				
Age at benzodiazepine start, median (IQR)	15.0 (12.0–16.0)	9.0 (7.0–11.0)	16.0 (15.0–17.0)	
Female	56.2	46.5	60.2	0.77 (0.76, 0.78)
Initial benzodiazepine				
Diazepam	30.0	42.0	25.1	1.67 (1.64, 1.71)
Lorazepam	24.2	21.8	25.1	0.87 (0.84, 0.89)
Alprazolam	18.5	9.9	22.0	0.45 (0.43, 0.47)
Clonazepam	21.5	20.4	22.0	0.93 (0.90, 0.95)
Triazolam	1.8	0.8	2.1	0.38 (0.33, 0.45)
Clobazam	0.8	2.2	0.3	7.70 (6.49, 9.14)
Other	3.2	2.9	3.4	0.86 (0.79, 0.93)
Potential indications, diagnoses prior 30 days				
Any potential indication	47.9	40.4	51.0	0.79 (0.78, 0.81)
Any potential indication including injury and musculoskeletal condition	66.6	62.0	68.4	0.91 (0.90, 0.92)
Mental health potential indication	39.0	23.0	45.4	0.51 (0.49, 0.52)
Anxiety disorder	27.6	17.2	31.7	0.54 (0.53, 0.56)
Unspecific anxiety	15.7	10.0	18.0	0.56 (0.53, 0.58)
Generalized anxiety disorder	7.9	5.0	9.1	0.55 (0.51, 0.58)
OCD	2.2	2.1	2.2	0.95 (0.85, 1.05)
PTSD	1.0	0.6	1.2	0.47 (0.40, 0.57)
Panic disorder	3.9	1.4	4.9	0.28 (0.25, 0.32)
Social phobia	1.0	0.4	1.3	0.31 (0.25, 0.39)
Other anxiety disorder ^a	2.7	2.3	2.9	0.81 (0.73, 0.89)
Sleep problems	3.1	2.7	3.3	0.80 (0.73, 0.87)
Bipolar disorder, schizophrenia, and other psychotic disorders	4.0	1.8	4.9	0.38 (0.35, 0.42)
Conduct/disruptive behavior disorders	2.2	2.7	2.0	1.38 (1.26, 1.51)
Depression	14.7	3.6	19.2	0.19 (0.17, 0.20)
Epilepsy, convulsions	6.3	12.5	3.8	3.33 (3.16, 3.51)
Movement disorders; muscle spasm ^b	5.9	9.8	4.4	2.23 (2.11, 2.35)
Other, uncommon ^c	0.2	0.2	0.2	0.95 (0.66, 1.37)
Injury ^d	12.5	12.9	12.4	1.04 (1.00, 1.08)
Musculoskeletal, connective tissue condition ^d	23.0	25.3	22.0	1.15 (1.12, 1.18)

^aOther anxiety disorder includes: separation anxiety disorder, agoraphobia, other phobia, selective mutism, other anxiety, anxiety owing to other conditions, acute stress disorder, and nervousness or other anxiety.

^bMovement disorder, muscle spasm: Muscle spasm, abnormal involuntary movement; cerebral palsy; tics; movement disorder; motor neuron diseases; muscular dystrophies/myopathies.

^cOther uncommon: alcohol withdrawal, burning mouth syndrome, trigeminal neuralgia, irritability/impulsive.

^dInjury (ICD-9-CM: 800–904, 910–957); Musculoskeletal, connective tissue condition (ICD-9-CM: 710-739.x); common diagnoses under 'musculoskeletal, connective tissue condition': spine curvature (3.4%, children=3.3%, adolescents=3.5%), pain in limb/joint (7.3%, children=7.2%, adolescents=7.3%), pain in neck/back (7.2%, children=7.1%, adolescents=7.3%).

OCD, obsessive—compulsive disorder; PR, prevalence ratio; PTSD, post-traumatic stress disorder.

Eleven percent of adolescent benzodiazepine initiators had a diagnosis for one or more of the prescribing cautions, including drug- (4%) and alcohol-related (1%) disorder diagnoses (Table 2). A higher proportion of child than adolescent initiators had selected sleep- or respiratory-related prescribing cautions. Seventeen

percent of benzodiazepine initiators had an opioid prescription dispensed on the day of the benzodiazepine initiation (Table 2). Recent opioid prescriptions were more prevalent in initiators with an injury or musculoskeletal condition diagnosis (children, 53%; adolescents, 48%) and in initiators with a recent inpatient

Table 2. Prescribing Cautions and Patient Characteristics of Children and Adolescents Initiating Prescription Benzodiazepine Treatment

Variable	Total, % (n=85,550)	Children, 3–12 years, % (n=24,504)	Adolescents, 13–17 years, % (n=61,046)	Child vs Adolescent, Crude PR (95% CI)
Prescribing cautions, prior year (unless specified)				
Drug-related disorder	2.8	0.5	3.8	0.12 (0.10, 0.15)
Alcohol-related disorder	0.8	0.1	1.1	0.08 (0.05, 0.12)
Suicidality (recorded self-harm, suicidal ideation)	3.7	0.7	4.9	0.15 (0.13, 0.17)
Poisoning	2.2	1.0	2.7	0.37 (0.32, 0.42)
Sleep apnea; hyposomnia	1.8	2.8	1.4	2.03 (1.84, 2.24)
Respiratory failure; hypoxemia (excludes day of BZD start)	1.2	2.4	0.7	3.29 (2.91, 3.72)
Any diagnosis above	9.8	6.7	11.0	0.61 (0.58, 0.64)
Opioid prescription				
Dispensed day of BZD start	16.9	17.9	16.5	1.08 (1.05, 1.12)
Dispensed in prior 30 days or day of BZD start	21.5	22.1	21.2	1.04 (1.01, 1.07)
>10 days supplied	4.4	5.3	4.1	1.28 (1.20, 1.37)
Provider contact, prior 30 days				
Mental health professional	25.5	18.2	28.4	0.64 (0.62, 0.66)
Psychiatrist	18.0	12.3	20.3	0.61 (0.58, 0.63)
Psychologist; therapist; psychiatric nurse	13.9	9.9	15.5	0.64 (0.61, 0.67)
General provider	50.4	49.6	50.8	0.98 (0.96, 0.99)
Pediatrician	24.6	33.1	21.3	1.55 (1.52, 1.59)
Family practice	17.4	10.5	20.1	0.52 (0.50, 0.54)
Internal medicine ^a	12.3	10.8	12.8	0.84 (0.81, 0.88)
Nurse practitioner; physician's assistant	3.6	3.4	3.6	0.96 (0.88, 1.03)
Specialist	30.1	37.5	27.1	1.38 (1.35, 1.41)
Neurology	7.6	11.6	6.0	1.94 (1.85, 2.03)
Surgery, radiology, anesthesiology	24.0	28.2	22.3	1.26 (1.23, 1.30)
Pediatrician specialty, other	8.0	11.9	6.5	1.83 (1.75, 1.92)
None of above	24.9	26.7	24.2	1.10 (1.07, 1.13)
Psychotropic prescription, prior 30 days ^b				
SSRI	25.2	14.1	29.7	0.48 (0.46, 0.49)
Other antidepressant	7.4	3.3	9.1	0.36 (0.34, 0.39)
Stimulant	9.2	9.6	9.1	1.06 (1.02, 1.11)
Antipsychotic	8.2	7.4	8.5	0.87 (0.82, 0.91)
Clonidine/guanfacine	3.8	6.7	2.6	2.54 (2.37, 2.72)
Additional characteristics				
Any mental health diagnosis, prior 30 days	48.2	36.3	53.0	0.68 (0.67, 0.70)
ADHD diagnosis, prior year	15.9	17.4	15.3	1.13 (1.09, 1.17)
Inpatient admission, prior 30 days				
Psychiatric related	4.1	2.7	4.7	0.57 (0.53, 0.62)
Nonpsychiatric related	9.7	15.1	7.5	2.02 (1.94, 2.10)
Discharged on BZD start date	7.5	10.0	6.5	1.56 (1.48, 1.63)
Complex chronic condition, prior year inpatient diagnoses ^c				
Neuromuscular, neurological	3.5	7.5	1.9	3.92 (3.65, 4.21)
Other congenital or genetic defect	3.2	3.8	3.0	1.25 (1.15, 1.35)
Malignancy	2.0	3.7	1.3	2.80 (2.55, 3.08)
Cardiovascular	1.6	2.0	1.4	1.38 (1.23, 1.54)

^aInternal medicine and medical doctor not classified under another specialty.

^bHypnotic, z-drug (children=0.2%, adolescents=1.1%), Hydroxyzine (children=1.8%, adolescents=2.2%); Multiple psychotropic classes: antidepressant + antipsychotic (children=2.9%, adolescents=4.9%); antidepressant + stimulant (children=3.0%, adolescents=4.2%), antidepressant + another class (children=6.4%, adolescents=10.0%).

^cMost common categories displayed (>1% of initiators).

ADHD, attention-deficit hyperactivity disorder; BZD, benzodiazepine; PR, prevalence ratio; SSRI, selective serotonin reuptake inhibitor.

Table 3. Long-Term Benzodiazepine Treatment (6 + Months) in Children and Adolescents by Potential Benzodiazepine Indication

Potential indication, diagnosis prior 30 days	Multiple potential indications allowed		Restricted to youth with one potential indication ^a	
	n (% of cohort)	% long-term BZD treatment (95% CI)	n (% of cohort)	% long-term BZD treatment (95% CI)
Children (n=24,504)				
Epilepsy	3,072 (13)	18.3 (17.0, 19.6)	1,939 (8)	18.4 (16.8, 20.1)
Bipolar; schizophrenia; conduct disorder	1,029 (4)	11.6 (9.8, 13.7)	392 (2)	9.3 (6.9, 12.6)
Sleep disorder	652 (3)	15.7 (13.2, 18.7)	284 (1)	15.3 (11.8, 19.8)
Depression	874 (4)	8.7 (7.0, 10.8)	230 (1)	10.2 (6.9, 15.0)
Anxiety disorder	4,218 (17)	7.1 (6.4, 7.9)	2,654 (11)	5.5 (4.7, 6.4)
Movement disorder, muscle spasm	2,395 (10)	9.4 (8.3, 10.6)	487 (2)	12.0 (9.5, 15.2)
Musculoskeletal condition	6,196 (25)	2.4 (2.1, 2.8)	2,873 (12)	0.8 (0.5, 1.2)
Injury	3,152 (13)	2.3 (1.8, 2.9)	1,094 (4)	1.2 (0.7, 2.0)
Any potential indication	15,204 (62)	7.3 (6.9, 7.7)	–	–
No potential indication	9,300 (38)	4.6 (4.2, 5.1)	–	–
Adolescents (n=61,046)				
Epilepsy	2,300 (4)	10.8 (9.7, 12.2)	1,157 (2)	10.0 (8.4, 11.8)
Bipolar; schizophrenia; conduct disorder	3,851 (6)	13.8 (12.7, 14.9)	1,286 (2)	14.6 (12.9, 16.7)
Sleep disorder	2,028 (3)	11.2 (9.9, 12.6)	651 (1)	10.3 (8.2, 12.8)
Depression	11,718 (19)	11.1 (10.5, 11.6)	4,077 (7)	10.5 (9.6, 11.5)
Anxiety disorder	19,374 (32)	9.0 (8.6, 9.4)	10,074 (17)	7.3 (6.8, 7.8)
Movement disorder, muscle spasm	2,680 (4)	7.3 (6.4, 8.4)	431 (1)	12.0 (9.4, 15.4)
Musculoskeletal condition	13,445 (22)	3.2 (2.9, 3.5)	5,500 (9)	1.9 (1.5, 2.3)
Injury	7,555 (12)	3.2 (2.9, 3.7)	1,894 (3)	1.7 (1.2, 2.4)
Any potential indication	41,783 (68)	7.4 (7.2, 7.7)	–	–
No potential indication	19,263 (32)	4.7 (4.4, 5.0)	–	–

^aFor example, 2,654 children (11% of children) had only a recent anxiety diagnosis and had no diagnosis for another potential indication (epilepsy, sleep disorder, bipolar/schizophrenia/conduct disorder, depression, muscle spasm/movement disorder, injury, musculoskeletal condition, other/uncommon) diagnosis in the prior 30 days; 'Other, uncommon' category is not displayed owing to low numbers but is included in restricted groups.

BZD, benzodiazepine.

admission (children, 65%; adolescents, 56%; data not shown).

Thirty percent of adolescents and 14% of children had a recent selective serotonin reuptake inhibitor prescription (Table 2). Recent nonpsychiatric inpatient admissions and complex chronic conditions were relatively common in benzodiazepine initiators (children, 15%; adolescents, 7%). Only 18% of children and 28% of adolescents had recent contact with a mental health specialist before the benzodiazepine initiation. In initiators with injury or musculoskeletal condition as a potential indication, 57% had recent contact with a provider in surgery, radiology, or anesthesiology (data not shown).

After excluding children (18%) and adolescents (12%) with a recent inpatient admission, the proportion with a potential benzodiazepine indication was similar (children, 58%; adolescents, 66%). Compared with the full cohort,

youth without a recent hospitalization had a lower proportion with opioid prescriptions, musculoskeletal condition diagnoses, and complex chronic conditions (Appendix Table 3, available online).

Overall, 6% (95% CI=6%, 7%) of children and 7% (95% CI=6%, 7%) of adolescents had long-term benzodiazepine treatment; 4% (children) and 3% (adolescents) with a 10-day grace period and 10% (children) and 12% (adolescents) with a 60-day grace period. By potential indication, the proportion with long-term use ranged from 3% of the initiators with an injury or musculoskeletal condition to 15% with epilepsy, with variation by age (Table 3). Long-term use estimates were largely consistent when restricting to youth with only one potential indication (Table 3).

In multivariable models for children (n=20,386) and adolescents (n=51,390) with 6 months of follow-up, potential indications of anxiety, depression, and bipolar

Table 4. Independent Predictors of Long-Term Benzodiazepine Treatment (6 + Months) in Children and Adolescents^{a,b}

Variable	Children (3–12 years)			Adolescents (13–17 years)		
	Total, n=20,386	Long-term use, (n=1,284)		Total, n=51,390	Long-term use, (n=3,477)	
		n	ARR (95% CI)		n	ARR (95% CI)
Female	9,441	580	1.05 (0.95, 1.17)	30,852	1,922	0.82 (0.76, 0.87)
Age at BZD start						
10–12 years (vs 3–9)	10,069	606	1.01 (0.91, 1.13)			–
16–17 years (vs 15–14)			–	29,058	2,092	1.14 (1.07, 1.22)
Potential indication, prior 30 days						
Epilepsy, convulsions	2,561	466	3.01 (2.61, 3.46)	1,952	217	1.70 (1.46, 1.98)
Bipolar disorder, schizophrenia, psychosis	387	44	1.02 (0.75, 1.39)	2,520	383	1.26 (1.12, 1.42)
Conduct/disruptive disorder	571	64	0.94 (0.74, 1.21)	1,026	125	0.95 (0.80, 1.13)
Sleep problems	544	86	1.72 (1.38, 2.16)	1,677	191	1.40 (1.21, 1.61)
Depression	724	63	0.98 (0.76, 1.28)	9,849	1,140	1.13 (1.04, 1.23)
Anxiety disorder	3,487	252	0.92 (0.78, 1.08)	16,125	1,501	1.13 (1.06, 1.21)
Muscle spasm, movement disorder	1,958	184	1.47 (1.25, 1.73)	2,247	167	1.32 (1.12, 1.54)
Musculoskeletal condition	5,090	122	0.65 (0.53, 0.79)	11,301	362	0.82 (0.73, 0.92)
Injury	2,609	60	0.86 (0.66, 1.12)	6,335	216	0.82 (0.72, 0.94)
Prescribing cautions, prior year						
Drug-related disorder			– ^c	1,910	247	1.16 (1.01, 1.33)
Alcohol-related disorder			– ^c	544	69	1.07 (0.84, 1.36)
Self-harm, suicidal ideation diagnosis	146	19	1.35 (0.86, 2.13)	2,484	329	1.00 (0.89, 1.14)
Poisoning	198	12	0.66 (0.38, 1.15)	1,389	163	1.02 (0.86, 1.20)
Sleep apnea, hypersomnia	582	90	1.58 (1.27, 1.95)	719	104	1.61 (1.34, 1.92)
Respiratory failure, hypoxemia	463	60	1.31 (1.00, 1.72)	364	38	1.83 (1.34, 2.49)
Opioid prescription, prior 30 day (ref=none)	15,918	1,244	Ref	40,531	3,274	Ref
Same day as BZD start	3,604	18	0.12 (0.08, 0.20)	8,387	52	0.16 (0.12, 0.21)
Prior 30 days (excluding day of BZD initiation)	864	22	0.50 (0.33, 0.76)	2,472	151	1.08 (0.92, 1.27)
Psychiatric inpatient admission, prior 30 days	544	71	1.16 (0.91, 1.47)	2,403	324	1.03 (0.90, 1.17)
Complex chronic condition	2,929	253	1.73 (1.48, 2.03)	3,765	188	1.18 (1.01, 1.38)
Health professional contact, prior 30 days						
Mental health specialist	3,760	368	1.46 (1.26, 1.69)	14,886	1,782	1.53 (1.42, 1.66)
General medical specialist	10,131	604	0.89 (0.80, 0.99)	26,217	1,675	0.91 (0.85, 0.97)
Neurology	2,406	312	1.19 (1.03, 1.38)	3,120	246	1.30 (1.12, 1.50)
Surgery, radiology, anesthesiology	5,773	200	0.68 (0.58, 0.80)	11,497	367	0.68 (0.60, 0.76)

^aModel includes children and adolescents with at least 6 months of continuous insurance enrollment after benzodiazepine initiation.

^bVariables not displayed but included in multivariable model (ARR, 95% CI): psychotropic prescriptions, prior 30 days for children (SSRI=1.23 [1.05, 1.45]; other antidepressant=1.46 [1.18, 1.81]; atomoxetine, hydroxyzine, clonidine, or guanfacine=1.46 [1.25, 1.69]; stimulant=1.13 [0.96, 1.32]; antipsychotic=1.45 [1.22, 1.72]) and adolescents (ARRs: SSRI=1.34 [1.25, 1.44]; other antidepressant=1.52 [1.40, 1.66]; hypnotic=1.60 [1.32, 1.95]; atomoxetine, hydroxyzine, clonidine, or guanfacine=1.38 [1.24, 1.53]; stimulant=1.25 [1.14, 1.37]; antipsychotic=1.45 [1.32, 1.59]); other specialized pediatrics provider contact: children=1.07 (0.91, 1.27), adolescents=0.94 (0.81, 1.09); Inpatient nonpsychiatric hospitalizations not included in model given concordance with complex chronic condition.

^cNot included in the multivariable model given the low number.

ARR, adjusted risk ratio; BZD, benzodiazepine.

disorder or schizophrenia independently predicted long-term use in adolescents but not children (Table 4). Recent contact with a mental health specialist (children, RR=1.46; adolescents, RR=1.53), recent psychotropic prescriptions, and complex chronic conditions were associated with an increased risk of long-term benzodiazepine use. Alternatively, contact with a specialist in surgery, radiology, or anesthesiology was associated with

a decreased likelihood of long-term use. Opioid prescriptions dispensed on the day of benzodiazepine initiation (children, RR=0.12; adolescents, RR=0.16; ref, no recent opioid prescription) was also associated with a decreased likelihood of long-term use. A recent opioid prescription dispensed before benzodiazepine initiation was not associated with a decreased likelihood of long-term use in adolescents.

DISCUSSION

Privately insured U.S. children and adolescents initiate benzodiazepine treatment for a variety of mental health and other medical indications, with anxiety disorders as the most common. The vast majority of youth discontinued benzodiazepine treatment early. Yet, a substantial proportion continued benzodiazepine treatment for 6 months or longer, despite recommendations calling for short-term treatment.^{28,29,61–64} In addition, in young benzodiazepine initiators, the prevalence of opioid prescriptions, substance use disorder diagnoses, and concurrent psychotropic use raise potential safety concerns.

In this study, approximately one fourth of children and one half of adolescents initiating benzodiazepine treatment had a mental health condition as a potential indication, similar to children (17%) and adolescents (53%) in Sweden.³³ The true proportions are likely higher, as a potential indication was not identified in one third of initiators, and the Swedish sample lacked diagnoses from primary care. Although sleep disorders are a prevalent indication of adult benzodiazepine use,^{3,11,65} and sleep disorders without anxiety are the most common preceding diagnosis in European databases,⁴ few young initiators with sleep disorder diagnoses were observed. This may be because of the differing clinical evidence and recommendations.^{30,66} In keeping with other studies from the U.S.,^{11,22} anxiety disorders were the most commonly observed potential indication, despite a lack of supporting evidence in pediatric anxiety disorders.^{26,27}

In European databases, 22%–82% of the benzodiazepine users had unknown indications.⁴ The fact that one third of the benzodiazepine initiators lack a potential indication in this study is likely related to unrecorded diagnoses on patient claims, unconfirmed diagnoses, symptoms not meeting diagnostic criteria, and indications outside the included definitions. Benzodiazepines could also be prescribed for preoperative medical visits or dental procedures,^{67,68} which are not captured consistently in claims data. Same-day opioid prescriptions and contact with providers in surgery, radiology, and anesthesiology suggest that youth initiate benzodiazepines surrounding medical procedures. Attention-deficit hyperactivity disorder and its pharmaceutical treatments were relatively prevalent in this young sample; the adverse effects of stimulants can include sleep disturbances.⁶⁹ Benzodiazepines could have been prescribed to treat medication side effects.

Most youth discontinued benzodiazepine treatment early. However, long-term use occurred, particularly in youth with epilepsy or mental health indications. There are clinical situations when long-term benzodiazepine

treatment may be an important component of illness management; yet, questions remain over long-term use.^{70,71} Under varying definitions, 6%–76% of use in adults involves long-term benzodiazepine treatment.¹² Importantly, many studies blend long-term use estimates from prevalent and incident users, which can vary substantially.⁷² Incident long-term use estimates were lower than estimates from a recent study (29%) in youth initiating benzodiazepine treatment.³³ Still, the observed long-term use in youth with depression diagnoses is particularly concerning, as benzodiazepines are not recommended for pediatric depression.^{73,74} Similar long-term treatment was observed in youth with anxiety (9%) and sleep disorder (12%) diagnoses despite recommendations.^{28,29} Clinical guidelines on discontinuing long-term benzodiazepine treatment are available for adults.^{75,76} Based on these findings, youth-specific guidelines are needed, which might involve determining whether benzodiazepine discontinuation interventions^{77,78} are effective for young users.

Concurrent opioid and benzodiazepine use is strongly discouraged given the increased mortality risk.^{9,79,80} Still, a fifth of young benzodiazepine initiators had recent opioid prescriptions, higher than the 13% of Swedish adolescents dispensed opioids.³³ In pediatric intensive care units, concurrent benzodiazepine and opioid use is common, with clinicians likely accustomed to managing patients safely.⁸¹ Opioid use was higher in recently hospitalized youth, suggesting a clinical need following hospital discharge. Relatedly, pediatric benzodiazepine initiators had relatively high morbidity with 15% of children having a past-year complex chronic condition. For comparison, 12% of children in an inpatient sample had a complex chronic comorbidity, as did 2% of children in an emergency department sample.⁵⁹

Benzodiazepine–psychotropic polypharmacy occurred in most adolescent benzodiazepine users in Finland,⁸² and three fourths of the children and young adults in Sweden had psychotropic medications surrounding benzodiazepine dispensing.³³ This polypharmacy and the concurrent psychotropic use in benzodiazepine initiators observed raises concerns owing to the unclear efficacy and safety of benzodiazepines used with other psychotropics. Given the range of benzodiazepine indications, benzodiazepine prescribers may be unaware of prior psychotropic prescriptions, opioid prescriptions, and substance use disorders. Improved care coordination could inform treating physicians of prior prescriptions and diagnoses.

Limitations

This analysis has some limitations. The authors were unable to link patient diagnoses to prescriptions,

resulting in uncertainty over the actual indication. The list of potential indications used in this study is not exhaustive given broad off-label use and ICD-9-CM code limitations. The prescriber and whether concurrent prescriptions came from multiple prescribers cannot be identified from the data; the data lack detailed clinical information. The data cover privately insured individuals and oversample individuals covered by large-sized employers. Different patterns of benzodiazepine use may occur among uninsured and Medicaid insured youth.⁸³ The results do not apply to nonbenzodiazepine hypnotics or sedatives. Dispensed medications may not have been taken, and youth may have had access to benzodiazepines outside the prescription. Finally, long-term use estimates are dependent on the days' supply values and selected grace period. Details on whether the benzodiazepine was prescribed for as-needed use are not available, which could allow for more flexible treatment duration definitions. The increase in long-term users under the extended grace period suggests that some youth take benzodiazepines as needed.

CONCLUSIONS

Benzodiazepines can be clinically useful medications when carefully prescribed to appropriate patients.²¹ However, they pose substantial risks.^{9,84} The authors cannot determine whether a strong therapeutic rationale guided each pediatric benzodiazepine prescription, but by characterizing patterns of benzodiazepine prescriptions to U.S. children and adolescents, this study identified areas of prescribing that can likely benefit from improvements. These areas include long-term benzodiazepine use, polypharmacy, prescribing cautions, and prescribing for conditions lacking empirical evidence.

ACKNOWLEDGMENTS

We thank Dr. Scott Bilder for his contributions to this manuscript. The National Institute of Mental Health (Bethesda, MD) provided funding for this paper under Award Number T32MH013043. The Agency for Healthcare Research and Quality provided grant support to Dr. Crystal from award numbers 1R01HS026001, 1U19HS021112, and R18HS023258, with additional support from PCORI IHS-1409-23194 and NIDA R01 DA047347.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Dr. Bushnell reported having received support from the National Institute of Mental Health under Award Number T32MH013043. Dr. Bushnell reported that she previously held

a graduate research assistantship with GlaxoSmithKline and was the Merck fellow for the Center for Pharmacoepidemiology at the University of North Carolina (both ended in December 2015). No other financial disclosures were reported.

SUPPLEMENTAL MATERIAL

Supplemental materials associated with this article can be found in the online version at <https://doi.org/10.1016/j.amepre.2019.07.006>.

REFERENCES

1. Olsson M, King M, Schoenbaum M. Benzodiazepine use in the United States. *JAMA Psychiatry*. 2015;72(2):136–142. <https://doi.org/10.1001/jamapsychiatry.2014.1763>.
2. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. *Am J Public Health*. 2016;106(4):686–688. <https://doi.org/10.2105/ajph.2016.303061>.
3. Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. *JAMA Netw Open*. 2019;2(1):e187399. <https://doi.org/10.1001/jamanetworkopen.2018.7399>.
4. Huerta C, Abbing-Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. *Pharmacoepidemiol Drug Saf*. 2016;25(suppl 1):56–65. <https://doi.org/10.1002/pds.3825>.
5. Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled substance prescribing patterns—Prescription Behavior Surveillance System, eight states, 2013. *MMWR Surveill Summ*. 2015;64(9):1–14. <https://doi.org/10.15585/mmwr.mmwr.ss6409a1>.
6. Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents—United States, 1999–2014. *JAMA*. 2018;319(19):2009–2020. <https://doi.org/10.1001/jama.2018.5690>.
7. McCabe SE, West BT. Medical and nonmedical use of prescription benzodiazepine anxiolytics among U.S. high school seniors. *Addict Behav*. 2014;39(5):959–964. <https://doi.org/10.1016/j.addbeh.2014.01.009>.
8. Brunton LL, Chabner BA, Knollmann BC (eds.). *Goodman & Gilman's the Pharmacological Basis of Therapeutics*, 12th ed. New York, NY: The McGraw-Hill Companies, Inc.; 2011.
9. Guina J, Merrill B. Benzodiazepines I: Upping the care on downers: the evidence of risks, benefits and alternatives. *J Clin Med*. 2018;7(2):17. <https://doi.org/10.3390/jcm7020017>.
10. Murphy KD, Sahn LJ, McCarthy S, Byrne S. Benzodiazepine prescribing guideline adherence and misuse potential in Irish minors. *Int J Clin Pharm*. 2015;37(5):749–752. <https://doi.org/10.1007/s11096-015-0138-8>.
11. Kaufmann CN, Spira AP, Depp CA, Mojtabei R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999–2014. *Psychiatr Serv*. 2018;69(2):235–238. <https://doi.org/10.1176/appi.ps.201700095>.
12. Kurko TA, Saastamoinen LK, Tahkapaa S, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. *Eur Psychiatry*. 2015;30(8):1037–1047. <https://doi.org/10.1016/j.eurpsy.2015.09.003>.
13. Yeh HH, Chen CY, Fang SY, et al. Five-year trajectories of long-term benzodiazepine use by adolescents: patient, provider, and medication factors. *Psychiatr Serv*. 2011;62(8):900–907. https://doi.org/10.1176/ps.62.8.pss6208_0900.
14. O'Sullivan K, Reulbach U, Boland F, et al. Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland. *BMJ Open*. 2015;5(6):e007070. <https://doi.org/10.1136/bmjopen-2014-007070>.

15. Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other anti-anxiety prescription medications. *J Clin Psychiatry*. 2018;79(1):16m11415. <https://doi.org/10.4088/jcp.16m11415>.
16. Warner M, Trinidad JP, Bastian BA, Minino AM, Hedegaard H. Drugs most frequently involved in drug overdose deaths: United States, 2010–2014. *Natl Vital Stat Rep*. 2016;65(10):1–15.
17. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999–2011. *NCHS Data Brief*. 2014;166:1–8.
18. Smink BE, Egberts AC, Luthof KJ, Uges DR, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. *CNS Drugs*. 2010;24(8):639–653. <https://doi.org/10.2165/11533170-000000000-00000>.
19. Rapoport MJ, Lanctot KL, Streiner DL, et al. Benzodiazepine use and driving: a meta-analysis. *J Clin Psychiatry*. 2009;70(5):663–673. <https://doi.org/10.4088/JCP.08m04325>.
20. Xing D, Ma XL, Ma JX, et al. Association between use of benzodiazepines and risk of fractures: a meta-analysis. *Osteoporos Int*. 2014;25(1):105–120. <https://doi.org/10.1007/s00198-013-2446-y>.
21. Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. *Am J Psychiatry*. 1991;148(2):151–152.
22. Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabei R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. *Pharmacoepidemiol Drug Saf*. 2016;25(6):637–645. <https://doi.org/10.1002/pds.3951>.
23. Parr JM, Kavanagh DJ, Young RM, McCafferty K. Views of general practitioners and benzodiazepine users on benzodiazepines: a qualitative analysis. *Soc Sci Med*. 2006;62(5):1237–1249. <https://doi.org/10.1016/j.socscimed.2005.07.016>.
24. Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. *Am J Geriatr Psychiatry*. 2010;18(12):1078–1092. <https://doi.org/10.1097/jgp.0b013e3181d6c0c6>.
25. Bandelow B, Reitt M, Rover, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. *Int Clin Psychopharmacol*. 2015;30(4):183–192. <https://doi.org/10.1097/yci.0000000000000078>.
26. Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. *JAMA Pediatr*. 2017;171(11):1049–1056. <https://doi.org/10.1001/jamapediatrics.2017.3036>.
27. Iper JC, Stein DJ, Hawkrigde S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. *Cochrane Database Syst Rev*. 2009(3):CD005170. <https://doi.org/10.1002/14651858.cd005170>.
28. Connolly SD, Bernstein GA, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46(2):267–283. <https://doi.org/10.1097/01.chi.0000246070.23695.06>.
29. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. *J Sleep Res*. 2017;26(6):675–700. <https://doi.org/10.1111/jsr.12594>.
30. Owens JA, Moturi S. Pharmacologic treatment of pediatric insomnia. *Child Adolesc Psychiatr Clin N Am*. 2009;18(4):1001–1016. <https://doi.org/10.1016/j.chc.2009.04.009>.
31. Witek MW, Rojas V, Alonso C, Minami H, Silva RR. Review of benzodiazepine use in children and adolescents. *Psychiatr Q*. 2005;76(3):283–296. <https://doi.org/10.1007/s11126-005-2982-5>.
32. Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. *Sleep Med*. 2010;11(7):692–700. <https://doi.org/10.1016/j.sleep.2009.11.015>.
33. Sidorchuk A, Isomura K, Molero Y, et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study. *PLoS Med*. 2018;15(8):e1002635. <https://doi.org/10.1371/journal.pmed.1002635>.
34. Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. *Psychiatr Serv*. 2019;70(2):97–106. <https://doi.org/10.1176/appi.ps.201800321>.
35. Maust DT, Blow FC, Wiechers IR, Kales HC, Marcus SC. National trends in antidepressant, benzodiazepine, and other sedative-hypnotic treatment of older adults in psychiatric and primary care. *J Clin Psychiatry*. 2019;78(4):e363–e371. <https://doi.org/10.4088/jcp.16m10713>.
36. Sawyer SM, Afifi RA, Bearinger LH, et al. Adolescence: a foundation for future health. *Lancet*. 2012;379(9826):1630–1640. [https://doi.org/10.1016/s0140-6736\(12\)60072-5](https://doi.org/10.1016/s0140-6736(12)60072-5).
37. IBM Watson health. MarketScan. <https://truenhealth.com/your-healthcare-focus/government/analytic-research/marketscan>. Accessed April 2, 2019.
38. Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A Consensus Meeting Summary. *J Clin Sleep Med*. 2005;1(1):49–59. <https://www.ncbi.nlm.nih.gov/pubmed/17561616>. Accessed January 16, 2018.
39. De Negri M, Baglietto MG. Treatment of status epilepticus in children. *Pediatr Drugs*. 2001;3(6):411–420. <https://doi.org/10.2165/00128072-200103060-00002>.
40. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published 2010. Accessed June 5, 2018.
41. Furukawa TA, Streiner D, Young LT, Kinoshita Y. Antidepressants plus benzodiazepines for major depression. *Cochrane Database Syst Rev*. 2001;3:CD001026. <https://doi.org/10.1002/14651858.cd001026>.
42. Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. *Cochrane Database Syst Rev*. 2013;4:CD003079. <https://doi.org/10.1002/14651858.cd003079.pub4>.
43. Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. *Cochrane Database Syst Rev*. 2012;11:CD006391. <https://doi.org/10.1002/14651858.cd006391.pub2>.
44. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. *West J Emerg Med*. 2012;13(1):26–34. <https://doi.org/10.5811/westjem.2011.9.6866>.
45. Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. *Eur J Clin Pharmacol*. 2012;68(5):833–844. <https://doi.org/10.1007/s00228-011-1188-z>.
46. Eddy CM, Rickards HE, Cavanna AE. Treatment strategies for tics in Tourette syndrome. *Ther Adv Neurol Disord*. 2011;4(1):25–45. <https://doi.org/10.1177/1756285610390261>.
47. Dahlin M, Knutsson E, Nergardh A. Treatment of spasticity in children with low dose benzodiazepine. *J Neurol Sci*. 1993;117(1–2):54–60. [https://doi.org/10.1016/0022-510x\(93\)90154-q](https://doi.org/10.1016/0022-510x(93)90154-q).
48. Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. *Cochrane Database Syst Rev*. 2006;(1):CD004762. <https://doi.org/10.1002/14651858.cd004762.pub2>.
49. Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. *J Trop Pediatr*. 2005;51(2):109–113. <https://doi.org/10.1093/tropej/fmh095>.
50. National Institute of Neurological Disorders and Stroke. Motor neuron diseases fact sheet. www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Motor-Neuron-Diseases-Fact-Sheet. Published 2012. Accessed July 19, 2018.
51. Quality Standards Subcommittee of the American Academy of Neurology the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of

- the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2010;74(4):336–343. <https://doi.org/10.1212/wnl.0b013e3181ec670b>.
52. Clark DB. Pharmacotherapy for adolescent alcohol use disorder. *CNS Drugs*. 2012;26(7):559–569. <https://doi.org/10.2165/11634330-000000000-00000>.
 53. Charleston L. Burning mouth syndrome: a review of recent literature. *Curr Pain Headache Rep*. 2013;17(6):336. <https://doi.org/10.1007/s11916-013-0336-9>.
 54. Zakrzewska JM. Medical management of trigeminal neuropathic pains. *Expert Opin Pharmacother*. 2010;11(8):1239–1254. <https://doi.org/10.1517/14656561003767449>.
 55. Loveless MS, Fry AL. Pharmacologic therapies in musculoskeletal conditions. *Med Clin North Am*. 2016;100(4):869–890. <https://doi.org/10.1016/j.mcna.2016.03.015>.
 56. Kaiser Permanente Guideline Oversight Group. Benzodiazepine and Z-drug safety guideline. <https://wa.kaiserpermanente.org/static/pdf/public/guidelines/benzo-zdrug.pdf>. Published 2014. Accessed June 19, 2018.
 57. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med*. 2007;147(7):478–491. <https://doi.org/10.7326/0003-4819-147-7-200710020-00006>.
 58. U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or. Published 2016. Accessed July 31, 2019.
 59. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. *BMC Pediatr*. 2014;14:199. <https://doi.org/10.1186/1471-2431-14-199>.
 60. Zou G. A modified Poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159(7):702–706. <https://doi.org/10.1093/aje/kwh090>.
 61. National Institute for Health and Care Excellence. Generalised Anxiety Disorder and Panic Disorder in Adults: Management. <https://www.nice.org.uk/guidance/cg113>. Published 2011. Accessed May 31, 2018.
 62. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive–compulsive disorders. *BMC Psychiatry*. 2014;14(suppl 1):S1. <https://doi.org/10.1186/1471-244x-14-s1-s1>.
 63. Lader M. Benzodiazepine harm: how can it be reduced? *Br J Clin Pharmacol*. 2014;77(2):295–301. <https://doi.org/10.1111/j.1365-2125.2012.04418.x>.
 64. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. *Prim Care Companion J Clin Psychiatry*. 2008;10(3):222–228. <https://doi.org/10.4088/pcc.v10n0307>.
 65. Rosman S, Le Vaillant M, Pelletier-Fleury N. Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study. *BMC Fam Pract*. 2011;12:28. <https://doi.org/10.1186/1471-2296-12-28>.
 66. Chhangani B, Greydanus DE, Patel DR, Feucht C. Pharmacology of sleep disorders in children and adolescents. *Pediatr Clin North Am*. 2011;58(1):273–291. <https://doi.org/10.1016/j.pcl.2010.11.003>.
 67. Wright KD, Stewart SH, Finley GA, Buffett-Jerrott SE. Prevention and intervention strategies to alleviate preoperative anxiety in children: a critical review. *Behav Modif*. 2007;31(1):52–79. <https://doi.org/10.1177/0145445506295055>.
 68. Donaldson M, Gizzarelli G, Chanpong B. Oral sedation: a primer on anxiolysis for the adult patient. *Anesth Prog*. 2007;54(3):118–128. [https://doi.org/10.2344/0003-3006\(2007\)54\[118:osapoa\]2.0.co;2](https://doi.org/10.2344/0003-3006(2007)54[118:osapoa]2.0.co;2).
 69. Graham J, Banaschewski T, Buitelaar J, et al. European guidelines on managing adverse effects of medication for ADHD. *Eur Child Adolesc Psychiatry*. 2011;20(1):17–37. <https://doi.org/10.1007/s00787-010-0140-6>.
 70. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? *Eur Neuropsychopharmacol*. 1999;9(suppl 6):S399–S405. [https://doi.org/10.1016/s0924-977x\(99\)00051-6](https://doi.org/10.1016/s0924-977x(99)00051-6).
 71. Neutel CI. The epidemiology of long-term benzodiazepine use. *Int Rev Psychiatry*. 2005;17(3):189–197. <https://doi.org/10.1080/09540260500071863>.
 72. Gray SL, Eggen AE, Blough D, Buchner D, LaCroix AZ. Benzodiazepine use in older adults enrolled in a health maintenance organization. *Am J Geriatr Psychiatry*. 2003;11(5):568–576. <https://doi.org/10.1097/00019442-200309000-00012>.
 73. Birmaher B, Brent D. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46(11):1503–1526. <https://doi.org/10.1097/chi.0b013e318145ae1c>.
 74. National Institute for Health and Care Excellence. Depression in Children and Young People: Identification and Management. <https://www.ncbi.nlm.nih.gov/pubmed/21834190>. Published 2005. Accessed August 15, 2018.
 75. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. *Can Fam Phys*. 2018;64(5):339–351. <https://www.ncbi.nlm.nih.gov/pubmed/29760253>. Accessed August 10, 2018.
 76. Canadian Agency for Drugs and Technologies in Health. Discontinuation Strategies for Patients With Long-Term Benzodiazepine Use: A Review of Clinical Evidence and Guidelines. www.cadth.ca/sites/default/files/rc0682-bzd_discontinuation_strategies_final_0.pdf. Published 2015. Accessed August 10, 2018.
 77. Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. *Br J Psychiatry*. 2014;204(6):471–479. <https://doi.org/10.1192/bjp.bp.113.134650>.
 78. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. *JAMA Intern Med*. 2014;174(6):890–898. <https://doi.org/10.1001/jamainternmed.2014.949>.
 79. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *MMWR Recomm Rep*. 2016;65(1):1–49. <https://doi.org/10.15585/mmwr.r6501e1>.
 80. Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. *BMJ*. 2017;356:j760. <https://doi.org/10.1136/bmj.j760>.
 81. Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of polypharmacy and potential drug–drug interactions among pediatric patients in ICUs of U.S. children’s hospitals. *Pediatr Crit Care Med*. 2016;17(5):e218–e228. <https://doi.org/10.1097/pcc.0000000000000684>.
 82. Gyllenberg D, Sourander A. Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. *Nord J Psychiatry*. 2012;66(5):336–342. <https://doi.org/10.3109/08039488.2011.644809>.
 83. Ali MM, Sherman LJ, Lynch S, Teich J, Mutter R. Differences in utilization of mental health treatment among children and adolescents with Medicaid or private insurance. *Psychiatr Serv*. 2019;70(4):329–332. <https://doi.org/10.1176/appi.ps.201800428>.
 84. Lembke A, Papac J, Humphreys K. Our other prescription drug problem. *N Engl J Med*. 2018;378(8):693–695. <https://doi.org/10.1056/nejmp1715050>.